靶向PD-1和LAG-3的双特异性分子tebotelimab治疗实体瘤和血液系统肿瘤:一项1期试验
这项1期剂量递增和队列扩展试验在既往治疗后进展的实体瘤或血液系统恶性肿瘤患者中评估tebotelimab(PD-1×LAG-3双特异性DART分子)单药(n=269)或联合抗HER2抗体margetuximab(n=84)的安全性和最大耐受剂量。单药组68%(184/269)发生治疗相关不良事件(22%为≥3级),未确定最大耐受剂量,推荐2期剂量为600 mg每2周一次;联合组74%(62/84)发生治疗相关不良事件(17%为≥3级),推荐2期剂量为600 mg每3周一次。
要点
- tebotelimab单药推荐2期剂量为600 mg每2周一次,未确定最大耐受剂量。
- 单药组68%(184/269)发生治疗相关不良事件,其中22%为≥3级。
- 联合margetuximab组确认客观缓解率为19%(14/72),推荐2期剂量为600 mg每3周一次。
核心结论
- tebotelimab单药或联合margetuximab在既往治疗后进展的实体瘤或血液系统恶性肿瘤患者中显示出临床安全性和抗肿瘤活性,未确定最大耐受剂量。
研究设计与样本
- 1期剂量递增和队列扩展临床试验,纳入既往治疗后疾病进展的实体瘤或血液系统恶性肿瘤患者,tebotelimab单药组n=269,联合margetuximab组n=84。
- 主要终点为tebotelimab单药或联合margetuximab的安全性和最大耐受剂量,次要终点包括抗肿瘤活性。
主要发现
- tebotelimab单药组68%(184/269)发生治疗相关不良事件,其中22%为≥3级;未确定最大耐受剂量,推荐2期剂量为600 mg每2周一次。
- 剂量递增队列中可评估疗效的患者34%(59/172)出现肿瘤缩小,在多种实体瘤类型中观察到客观缓解,包括PD-1难治性疾病,以及LAG-3+非霍奇金淋巴瘤,包括CAR-T难治性疾病。
- tebotelimab联合margetuximab组74%(62/84)发生治疗相关不良事件,其中17%为≥3级;推荐2期剂量为600 mg每3周一次。
- 联合margetuximab组确认客观缓解率为19%(14/72),包括通常对anti-HER2/anti-PD-1联合治疗无应答的患者中出现缓解。
关键数值与推荐
- tebotelimab单药推荐2期剂量为600 mg每2周一次。
- tebotelimab联合margetuximab推荐2期剂量为600 mg每3周一次。
- tebotelimab单药组治疗相关不良事件发生率68%(184/269),≥3级22%。
- tebotelimab联合margetuximab组治疗相关不良事件发生率74%(62/84),≥3级17%。
- tebotelimab联合margetuximab组确认客观缓解率19%(14/72)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tebotelimab, a bispecific PD-1×LAG-3 DART molecule that blocks both PD-1 and LAG-3, was investigated for clinical safety and activity in a phase 1 dose-escalation and cohort-expansion clinical trial in patients with solid tumors or hematologic malignancies and disease progression on previous treatment. Primary endpoints were safety and maximum tolerated dose of tebotelimab when administered as a single agent (n = 269) or in combination with the anti-HER2 antibody margetuximab (n = 84). Secondary endpoints included anti-tumor activity. In patients with advanced cancer treated with tebotelimab monotherapy, 68% (184/269) experienced treatment-related adverse events (TRAEs; 22% were grade ≥3). No maximum tolerated dose was defined; the recommended phase 2 dose (RP2D) was 600 mg once every 2 weeks. There were tumor decreases in 34% (59/172) of response-evaluable patients in the dose-escalation cohorts, with objective responses in multiple solid tumor types, including PD-1-refractory disease, and in LAG-3+ non-Hodgkin lymphomas, including CAR-T refractory disease. To enhance potential anti-tumor responses, we tested margetuximab plus tebotelimab. In patients with HER2+ tumors treated with tebotelimab plus margetuximab, 74% (62/84) had TRAEs (17% were grade ≥3). The RP2D was 600 mg once every 3 weeks. The confirmed objective response rate in these patients was 19% (14/72), including responses in patients typically not responsive to anti-HER2/anti-PD-1 combination therapy. ClinicalTrials.gov identifier: NCT03219268 .
引用
- Luke JJ, Patel MR, Blumenschein GR, et al. The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med. 2023. PMID: 37857711. doi:10.1038/s41591-023-02593-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。